推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
药品控制
USDEA Schedule IV
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
生化/生理作用
Potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of DA and NE in vivo
Solriamfetol (JZP-110) is a potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of dopamine and norepinephrine in vivo. Solriamfetol is a wake-promoting agent.
注意
Hygroscopic
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Stefano de Biase et al.
Expert opinion on investigational drugs, 26(8), 953-963 (2017-07-21)
Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. While non-pharmacological treatments are sometimes helpful, more than 90% of narcoleptic patients require a pharmacological treatment.
Richard K Bogan et al.
Sleep medicine, 16(9), 1102-1108 (2015-08-25)
JZP-110 is a wake-promoting agent with dopaminergic and noradrenergic activity. This double-blind, crossover study, randomized adults with narcolepsy with or without cataplexy (N = 33) to placebo or JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4).
Michelle G Baladi et al.
The Journal of pharmacology and experimental therapeutics, 366(2), 367-376 (2018-06-13)
Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration-approved drugs that act
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门